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Abstract The similarity of atrophy patterns in Alzhei-
mer’s disease (AD) and in normal aging suggests age as a
confounding factor in multivariate models that use struc-
tural magnetic resonance imaging (MRI) data. To study the
effect and compare different age correction approaches on
AD diagnosis and prediction of mild cognitive impairment
(MCI) progression as well as investigate the characteristics
of correctly and incorrectly classified subjects. Data from
two multi-center cohorts were included in the study
[AD = 297, MCI = 445, controls (CTL) = 340]. 34 cor-
tical thickness and 21 subcortical volumetric measures
were extracted from MRI. The age correction approaches
involved: using age as a covariate to MRI-derived mea-
sures and linear detrending of age-related changes based on
CTL measures. Orthogonal projections to latent structures
was used to discriminate between AD and CTL subjects,
and to predict MCI progression to AD, up to 36-months
follow-up. Both age correction approaches improved
models’ quality in terms of goodness of fit and goodness of
prediction, as well as classification and prediction accura-
cies. The observed age associations in classification and
prediction results were effectively eliminated after age
correction. A detailed analysis of correctly and incorrectly
classified subjects highlighted age associations in other
factors: ApoE genotype, global cognitive impairment and
gender. The two methods for age correction gave similar
results and show that age can partially masks the influence
of other aspects such as cognitive impairment, ApoE-e4
genotype and gender. Age-related brain atrophy may have
a more important association with these factors than pre-
viously believed.
Keywords OPLS  Age correction  Alzheimer’s disease 
Mild cognitive impairment  MRI  Early diagnosis 
Diagnostic misclassification
Data used in preparation of this article were obtained from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). As such, the investigators within the ADNI
contributed to the design and implementation of ADNI and/or
provided data but did not participate in analysis or writing of this
report. A complete listing of ADNI investigators can be found at:
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_
Acknowledgement_List.pdf.
Electronic supplementary material The online version of this
article (doi:10.1007/s10548-015-0455-1) contains supplementary
material, which is available to authorized users.
& Farshad Falahati
farshad.falahati@ki.se
1 Department of Neurobiology, Care Sciences and Society,
Karolinska Institutet, Novum, Plan 5, 141 57 Stockholm,
Sweden
2 Department of Neurology, University of Eastern Finland and
Kuopio University Hospital, Kuopio, Finland
3 Institute of Gerontology and Geriatrics, University of
Perugia, Perugia, Italy
4 INSERM U 558, University of Toulouse, Toulouse, France
5 3rd Department of Neurology, Medical School, Aristotle
University of Thessaloniki, Thessaloniki, Greece
6 Medical University of Lodz, Lodz, Poland
7 Institute of Psychiatry, King’s College London, London, UK
8 NIHR Biomedical Research Centre for Mental Health,
London, UK
123
Brain Topogr (2016) 29:296–307
DOI 10.1007/s10548-015-0455-1
Introduction
Alzheimer’s disease (AD), the most common form of
dementia, is a progressive neurodegenerative disorder that
clinically characterizes by gradual loss of cognitive
functions. Mild cognitive impairment (MCI), an interme-
diate condition between normal cognition and dementia,
often represents a prodromal form of dementia. MCI
patients have a significantly higher risk of converting to
AD or other types of dementia. However not all MCI
patients develop dementia even after several years. The
new criteria for diagnosing ‘‘dementia due to AD’’ and
‘‘MCI due to AD’’ in addition to core clinical criteria,
include the use of imaging and other biomarkers to
improve the certainty of diagnoses (Albert et al. 2011;
McKhann et al. 2011). However, the need of additional
work to validate these biomarkers for routine clinical
practice is also noted.
Structural magnetic resonance imaging (MRI) is an
important marker in clinical practice for dementia diag-
nosis, particularly in memory clinic settings when younger
and rare conditions are examined (Falahati et al. 2014a).
MRI has been widely studied for early detection and
diagnosis of AD in terms of atrophy of brain structures. In
particular, atrophy of medial temporal structures such as
hippocampus is demonstrated in AD patients (Scheltens
et al. 1992). Due to the complexity of AD, measures of
single structures from MRI are probably insufficient for
accurate diagnosis. The combination of different structures
has proven to be more useful when distinguishing AD from
cognitively normal elderly subjects (CTL) (Westman et al.
2011b). With the help of sophisticated image analysis
techniques, numerous volumetric and cortical thickness
measures can be extracted from structural MRI data.
Machine learning and multivariate data analysis meth-
ods provide tools for processing and finding inherent pat-
terns in such data with high complexity and dimensionality.
Methods like orthogonal projection to latent structures
(OPLS) (Bylesjo¨ et al. 2006; Trygg and Wold 2002) are
efficient, robust and validated tools for modeling complex
biological data. OPLS was developed with the aim of
reducing model complexity and improving model trans-
parency. The improved interpretation property of the OPLS
method postures it as a suitable analysis method. OPLS has
successfully been applied in research for AD diagnosis and
prediction of MCI progression (Aguilar et al. 2014; Spulber
et al. 2013).
Confounding factors such as age negatively affect the
performance of machine learning and multivariate models.
Global and regional brain changes related to increasing age
can potentially lead to misclassification of younger AD
patients and older CTL subjects. Therefore, there is a need
for developing methods to address this problem. Recently
several methods for correcting the age associations are
proposed (Dukart et al. 2011; Koikkalainen et al. 2012).
The focus of these studies are statistical improvements
while their effects on the characteristics of correctly and
incorrectly classified subjects were disregarded. Studying
the subjects’ characteristics is of high importance since it
can distinctly reflect the way age correction improves the
outcomes. Further, to compare these methods to simply use
age as a covariate has not been properly investigated.
In this work two age correction approaches were
investigated: simply using age as a variable in the OPLS
model and a linear detrending approach that removes age-
related effects from each variable based on measures in
CTL subjects. The effect of age correction approaches on
the classification of AD and CTL subjects, and prediction
of progression from MCI to AD was explored. The char-
acteristics of correctly/incorrectly classified and predicted
subjects before and after age correction were studied in
detail. We hypothesized that age correction would improve
the performance of both classification and prediction.
Additionally, studying the characteristics of subjects before
and after age correction may reveal other clinically rele-
vant aspects.
Materials and Methods
Study Setting
Data were obtained from two large multi-center cohorts,
the Alzheimer’s disease Neuroimaging Initiative (ADNI)
database (http://adni.loni.usc.edu) and AddNeuroMed.
ADNI was launched in 2003 by the National Institute on
Aging (NIA), the National Institute of Biomedical Imaging
and Bioengineering (NIBIB), the Food and Drug Admin-
istration (FDA), private pharmaceutical companies and
non-profit organizations (Mueller et al. 2005). The primary
goal of ADNI is to test whether serial MRI, PET, other
biological markers, and clinical and neuropsychological
assessments can be combined to measure the progression of
MCI and early AD. The Principal Investigator of this ini-
tiative is Michael W. Weiner, MD, VA Medical Center and
University of California -San Francisco. ADNI subjects
were recruited from over 50 sites across the U.S. and
Canada. For up-to-date information, see www.adni-info.
org. AddNeuroMed, a part of InnoMed (Innovative
Medicines in Europe), is an integrated project aimed to
develop and validate novel surrogate markers in AD
(Lovestone et al. 2007). The neuroimaging part of
AddNeuroMed uses MRI collected from six different sites
across Europe (http://www.innomed-addneuromed.com/).
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A total of 1082 subjects were included in the current
study (AD = 297, MCI = 445 and CTL = 340). At
12-month follow-up, 85 MCI patients progressed to AD
(MCI-p) and 360 remained stable (MCI-s). The demo-
graphics of the dataset are given in Table 1. The subjects in
the ADNI study have also been followed up at 18, 24 and
36 months after baseline. MCI individuals who progressed
to AD were considered as MCI-p and the rest as MCI-s.
Inclusion and Diagnostic Criteria
Participants’ recruitment and eligibility criteria were very
similar in both cohorts (Petersen et al. 2010; Simmons et al.
2011). Briefly, AD diagnosis was based on NINCDS-
ADRDA and DSM-IV criteria for probable AD, as well as
a total clinical dementia rating (CDR) score of 0.5 or
above. MCI diagnosis required a MMSE score between 24
and 30; memory complaints; normal activities of daily
living; total CDR score of 0.5; and Geriatric Depression
Scale (GDS) score of B5. The inclusion criteria for control
participants were a MMSE score between 24 and 30; total
CDR score of 0; and GDS score B5. No significant neu-
rological or psychiatric illness, no significant unstable sys-
temic illness or organ failure, and no history of alcohol or
substance abuse or dependence were required for all three
groups. MRI information was not used for diagnosis.
Imaging
MRI Data Acquisition
In both cohorts, 1.5T MRI data was collected from a
variety of MR-systems with protocols optimized for each
type of scanner. The MRI protocol included a high-
resolution sagittal 3D T1-weighted MPRAGE volume
(voxel size 1.1 9 1.1 9 1.2 mm3) acquired using a cus-
tom pulse sequence specifically designed for the ADNI
study to ensure compatibility across scanners (Jack et al.
2008). MRI data acquisition in AddNeuroMed was
designed to be compatible with the ADNI protocol
(Simmons et al. 2011).
Regional Subcortical Volume Segmentation
and Cortical Thickness Parcellation
The FreeSurfer pipeline (version 5.3.0) was applied to the
MRI images to produce regional cortical thickness and
subcortical volumetric measures. Full details and refer-
ences of cortical reconstruction and subcortical volumetric
segmentation procedure are included in the supplementary
material 1. Data was processed through the hive database
system (theHiveDB) (Muehlboeck et al. 2014). Visual
quality control was performed on all output data. All steps
involving brain extraction, automated Talairach transfor-
mation, tessellation, surfaces reconstruction, and subcor-
tical segmentation were carefully checked. This
segmentation approach has been used for multivariate
classification of Alzheimer’s disease and healthy controls
(Westman et al. 2010), neuropsychological-image analysis
(Ferreira et al. 2014) and biomarker discovery (Maioli
et al. 2015). In total, 55 MRI measures were used as input
variables for OPLS classification, i.e. 34 regional cortical
thickness measures and 21 regional subcortical volumes
(measures from the left and right sides were averaged).
Supplementary material 2 provides a list of measures and
their mean and standard deviation in each diagnostic
group. All subcortical volumetric and cortical thickness
measures were used in their raw form (Westman et al.
2013).
Table 1 Demographic and
clinical characteristics
CTL MCI-s MCI-pa AD
Count 340 360 85 297
Age, years 75.0 ± 5.7 75.0 ± 6.9 74.3 ± 6.5 75.7 ± 7.0
Gender, Female/Male 172/168 141/219 35/50 165/132
Education, years 14.3 ± 4.3 13.9 ± 4.7 13.8 ± 4.2 12.0 ± 4.9
MMSE score 29.1 ± 1.1 27.1 ± 1.7 26.5 ± 1.8 22.2 ± 3.7
CDR 0 0.5 0.5 0.92 ± 0.43
ApoE-e4, N/P 242/92 182/158 31/52 110/178
Cohort, ADNI/ANM 227/113 260/100 62/23 175/122
Continuous data is represented as mean ± SD, CTL control subjects, MCI mild cognitive impairment, MCI-
s stable MCI, MCI-p progressive MCI, AD Alzheimer’s disease, MMSE mini mental state examination,
CDR clinical dementia rating, ApoE apolipoprotein E, N/P negative/positive for at least one e4 allele,
ADNI/ANM Alzheimer’s Disease Neuroimaging Initiative/AddNeuroMed
a MCI patients progressed to AD at month-12 follow-up
298 Brain Topogr (2016) 29:296–307
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Data Analysis
Multi and Univariate Data Analysis
Pre-processing was performed using mean-centering and
unit variance scaling in order to transform the data into a
suitable form for analysis (Eriksson et al. 2013). OPLS
(Bylesjo¨ et al. 2006; Trygg and Wold 2002), a supervised
multivariate data analysis method, was used to classify AD
patients and CTL individuals as well as to predict pro-
gression in the MCI patients. The OPLS method is an
extension to the projection to latent structures (PLS)
method (Wold et al. 1984). PLS has been developed for the
purpose of modeling complex data based on the assump-
tion that there are latent variables, which generate the
observed data. PLS extracts these latent variables by
maximizing the covariance between two sets of data,
descriptor and response variables. In OPLS, the systematic
variation in descriptor data is separated into two blocks,
predictive variation correlated to response data and non-
predictive variation orthogonal to response data. This
separation improves the model transparency and reduces
the model complexity. OPLS and PLS provide the same
predictive accuracy, however, particularly for the two-class
discriminant problem OPLS has an advantage over PLS
that provides only one single predictive component (first
component) and the other orthogonal components (if any)
are not important in class separation. Accordingly, one
single loading vector describes the class discriminating
variables.
The performance of an OPLS model is quantified by two
parameters, the goodness of fit (R2) and the goodness of
prediction (Q2) (Eriksson et al. 2013). R2 is the fraction of
variation of the training data that can be explained by the
components of the model. R2 shows how well the model
fits the training data. Q2 is the fraction of variation of the
training data that can be predicted by the model. Q2 shows
how reliable the model predicts new data. Q2 is used to find
the optimal model complexity, which results in the most
valid model with a balance between fit and predictive
ability. Therefore, Q2 is more important than R2 and a
model with higher Q2 is consider as a better model. Q2 is
estimated by cross validation (CV). CV is a practical
approach for evaluating learning algorithms that is based
on building of a number of parallel models (Wold 1978). In
this work, sevenfold CV was used to calculate Q2. In
addition to Q2 and R2 as performance metrics, classifica-
tion success rates were reported in terms of the accuracy,
sensitivity and specificity.
For univariate comparisons of quantitative and qualita-
tive variables, the independent samples t test and the v2 test
were used respectively.
Age Correction Methods
Two age correction methods were implemented: (1) a
simple approach that treats age as a covariate and includes
age in the OPLS model as a separate variable along with
MRI-derived variables and (2) a linear detrending algo-
rithm based on age-related changes in the CTL group only.
The detrending algorithm fits a generalized linear model
(GLM) to each MRI-derived variable and age, in the CTL
group only, and models the age-related changes as a linear
drift. Then, the regression coefficient of the resulted GLM
model (linear drift) is used to remove the age-related
changes from all individuals (AD, MCI and CTL) and
obtain corrected values. The linear model was chosen
based on the Good et al. (2001) study where they found an
age-related linear decrease in global grey matter volume in
healthy individuals. The assumption for age correction
method is that the age related changes in the CTL group are
due to aging, while the age related changes in the MCI/AD
group includes disease-related changes as well. Therefore,
the algorithm calculates age-related effects based on the
CTL group only, since removing age-related changes based
on the AD or MCI group might also remove the disease-
related changes. The detrending method was applied prior
to further statistical analysis.
Implementation
In the first step, three OPLS models were created for
classification of AD and CTL subjects: (1) a model based
on the raw measures (uncorrected model), (2) a model
using age as a covariate (covariate model) and (3) a model
based on age-detrended measures (detrended model).
Subsequently, the resulted classification models were used
to predict MCI patients as unseen data.
The output of the OPLS model is a cross-validated score
vector where each score corresponds to one subject. A
subject with a score close to one displays a pattern similar
to AD and a subject with a score close to zero displays a
pattern similar to CTL. A fixed cut-off equal to 0.5 was
used to assign class membership to the predicted scores and
afterwards to calculate accuracy, sensitivity and specificity
(Spulber et al. 2013). Similarly, the prediction result for
MCI patients is a score vector and by applying an appro-
priate cut-off (0.5), MCI patients can be predicted as CTL-
like/AD-like. These steps were conducted for each age
correction method.
All models were created hierarchically, i.e. volumetric
and thickness measures were analyzed separately, and the
output scores of these base models were used to create the
final model. In the simple age correction method, age was
included in the model along with base scores.
Brain Topogr (2016) 29:296–307 299
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Results
Table 2 summarizes the results from the analyses. The
OPLS model based on the original MRI variables (uncor-
rected model) resulted in Q2 = 0.567 and R2 = 0.568. The
model using original MRI data and age as a covariate
(covariate model) resulted in Q2 = 0.580 and R2 = 0.586.
The model based on age corrected MRI data (detrended
model) resulted in Q2 = 0.582 and R2 = 0.583. The clas-
sification of AD and CTL subjects with uncorrected model
resulted in an accuracy = 86.7 %, the covariate model
resulted in an accuracy = 87.3 % and the detrended model
resulted in an accuracy = 88.2 %. MCI prediction using
the uncorrected model resulted in an accuracy = 62.7 %,
the covariate model resulted in an accuracy = 62.9 % and
finally the accuracy of the detrended model was 65.0 %.
Medial temporal structures including amygdala, entorhi-
nal cortex and hippocampus and the temporal gyrus regions
(inferior, middle and superior) were the most important
variables for the separation between the AD and CTL group
in all three models. Figure 1 shows the thickness values of
entorhinal cortex before and after applying age correction in
the different groups. The Pearson correlation coefficients
between all MRI measures and age, before and after age
correction are given in supplementary material 3.
Table 3 shows the prediction results for the MCI sub-
jects from the ADNI cohort at the different follow-up time
points. At each time point, the detrended model resulted in
the highest accuracy among the three models. In the
uncorrected model, by increasing the follow-up duration
from 12 months to 36 months, the prediction accuracy was
improved from 60.9 to 66.8 %. In the detrended model, the
prediction accuracy rose from 63.0 to 70.8 %.
Additional analyses were performed to further investi-
gate the effect of the age correction methods on classifi-
cation and prediction models. Table 4 shows the
comparison between correct and incorrect classified sub-
jects within each diagnostic group (i.e. within AD and CTL
group) and the comparison of incorrect classified subjects
between AD and CTL subjects. Without age correction,
within both the CTL and the AD group, the mean age of
correctly and incorrectly classified subjects was signifi-
cantly different (p\ 0.001 and p = 0.006, respectively).
After accounting by age, both the covariate and detrended
models showed no statistically significant age difference.
The mean age of the incorrect classified CTL and AD
subjects were 79.1 and 73.3 years, respectively (p\ 0.001)
in the uncorrected model. This difference was eliminated in
both the covariate and detrended models. The MMSE score
of AD subjects was significantly higher in incorrectly
classified subjects in all three models. Moreover, the dis-
tribution of ApoE-e4 genotype was significantly different
between incorrectly classified CTL and AD subjects.
Table 5 shows the comparison between correctly and
incorrectly predicted MCI patients within each group (i.e.
within MCI-s and MCI-p group) as well as the comparison
of incorrectly predicted subjects between MCI-s and MCI-
p group. In MCI-s subjects, the mean age of correctly and
incorrectly predicted subjects was significantly different
without considering age (p\ 0.001) but not after
accounting for age. Using uncorrected data resulted in
3.9 years difference between the mean-age of misclassified
MCI-p and MCI-s (p = 0.003), where incorrectly predicted
MCI-s patients were older than incorrectly classified MCI-
p subjects (77.0 and 73.1 years respectively). This differ-
ence was eliminated after age correction. Moreover,
incorrectly predicted MCI-s patients showed significantly
lower MMSE score and lower frequency of male in all
three models. In addition, age correction led to a significant
difference in ApoE-e4 distribution in MCI-s subjects,
showing lower frequency of ApoE-e4 allele in incorrectly
predicted subjects.
Discussion
In recent years, there has been an increased interest in
using advanced machine learning and multivariate data
analysis methods and structural MRI data for early diag-
nosis of AD. Notably, the discriminative capacity of MRI-
derived features and several classifiers for classifying AD
patients and CTL individuals and for predicting
Table 2 AD classification and MCI prediction results
Model Q2 R2 Accuracy % Sensitivity % Specificity %
AD versus CTL classification (CV) Uncorrected 0.567 0.568 86.7 81.8 90.9
Covariate 0.580 0.586 87.3 81.5 92.4
Detrended 0.582 0.583 88.2 82.8 92.9
MCI prediction Uncorrected – – 62.7 70.2 60.9
Covariate – – 62.9 71.4 60.9
Detrended – – 65.0 75.0 62.6
AD Alzheimer’s disease, CTL control subjects, MCI mild cognitive impairment, CV cross-validated, Q2 goodness of prediction, R2 goodness of fit
300 Brain Topogr (2016) 29:296–307
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progression from MCI to AD has been investigated (Liu
et al. 2013; Wee et al. 2013; Wolz et al. 2011). The OPLS
method in this work resulted in high classification accuracy
and good prediction outcomes. OPLS has previously been
used for classification purposes in the same two multi-
center cohorts considered here (Westman et al. 2011a).
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Fig. 1 The blue, green and cyan markers represent the entorhinal
cortex thickness of CTL, AD and MCI subjects before and after age
correction with detrending method: a CTL subjects before age
correction, b CTL subjects after age correction, c AD patients before
age correction, d AD patients after age correction, e MCI patients
before age correction and f MCI patients after age correction. Each
marker corresponds to one subject. The red lines indicate the age-
related drift fitted in the groups (Color figure online)
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Despite the input data (dataset subjects) and image pro-
cessing (FreeSurfer software version) are non-identical in
the two studies, the accuracy levels were analogous. It has
previously been shown that different advanced classifiers
applied to the same data provide similar levels of accuracy
(Aguilar et al. 2013). At present, limitations are probably
related to input data (quality of data or cohort studied),
clinical diagnosis or the confounding effect of some
demographic variables such as age, rather than the method
used for classification (Falahati et al. 2014b).
Age as a confounding factor can negatively affect the
classification and prediction performance. Indeed, the
similarity of atrophy patterns in AD patients and in cog-
nitively normal subjects can lead to misclassification of
young AD patients and old CTL subjects. Global and
regional changes of brain volumes in normal aging have
been reported in cross-sectional and longitudinal brain
imaging studies (Giorgio et al. 2010; Good et al. 2001;
Scahill et al. 2003; Walhovd et al. 2005). Additionally,
several studies have reported that brain atrophy accelerates
with disease progression in AD and other types of dementia
(Fox et al. 1996; Jack et al. 2004; Sabuncu et al. 2011;
Tisserand et al. 2004). Particularly, global brain atrophy
and reduced volume in the temporal lobe especially in
hippocampus and entorhinal cortex have been reported.
Using age as a covariate in statistical models is a
common way to deal with this problem. Recently, new
approaches such as a data correction method based on
linear regression models (Dukart et al. 2011; Koikkalainen
et al. 2012), and confounder correcting support vector
machine algorithm (Li et al. 2011) have been proposed to
more effectively control for the effect of age as a con-
founding factor. In this study, two approaches i.e. age as a
covariate and deterending age-related changes were
investigated. Both studied approaches here have pros and
cons. In heterogeneous populations containing AD, MCI
and CTL subjects with different patterns and rates of
atrophy simply using age as a covariate may not be an
optimal approach. However, the OPLS method seems to be
able to handle age as a covariate. Detrending age-related
changes is challenging since modeling the exact associa-
tion between age and discriminative features and subse-
quently remove such associations can be difficult and time
consuming. One of the main ideas behind the detrending
method was to remove age-related changes while pre-
serving the disease-related changes for each variable sep-
arately. The hypothesis was that by detrending the AD and
the MCI group based on CTL group, the age-related
changes would be omitted and the disease-related changes
would be kept. Therefore the control group should be
representative of population and equally distributed on the
age range. Hence the detrending method may be more
effective in a larger dataset. In some variables (e.g. hip-
pocampus) the slopes for MCI and AD were slightly tilted
in the opposite direction after age correction, indicating
that the algorithm may overcorrect in older AD and MCI
cases. A reduction in rates of atrophy in older AD and MCI
compared to CTL could be a possible explanation for the
observed pattern. A recent study has shown that a pro-
nounced reduction in rates of atrophy can be observed in
AD and MCI individuals with increasing age, while for
cognitively normal individuals, increasing age leads to
increased rates of atrophy (Holland et al. 2012).
The results indicate that when age is included, the
quality of models in terms of the goodness of fit and more
importantly the goodness of prediction was improved
which led to higher classification and predication accura-
cies. Although accurate discrimination between AD
patients and CTL subjects is of great interest, prediction of
progression form MCI to AD is more valuable since it can
provide an opportunity for early detection of individuals
under risk of developing dementia. Generally, MCI
Table 3 Prediction results for
MCI subjects of ADNI cohort at
different follow-up time points
Time point Model Accuracy % Sensitivity % Specificity %
Month-12
MCI-p = 62, MCI-s = 260
Uncorrected 60.9 72.1 58.2
Covariate 60.2 70.5 57.9
Detrended 63.0 75.4 60.2
Month-18
MCI-p = 90, MCI-s = 232
Uncorrected 64.9 72.2 62.1
Covariate 66.1 74.4 62.9
Detrended 67.7 75.6 64.7
Month-24
MCI-p = 126, MCI-s = 196
Uncorrected 65.5 66.7 64.8
Covariate 67.4 69.0 66.3
Detrended 68.9 69.8 68.4
Month-36
MCI-p = 150, MCI-s = 172
Uncorrected 66.8 65.3 68.0
Covariate 69.3 68.0 70.3
Detrended 70.8 68.7 72.7
MCI mild cognitive impairment, MCI-s stable MCI, MCI-p progressive MCI
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prediction accuracy is not as good as classification of AD
and CTL subjects. Reviewing the literature, classification
accuracies tend to range between 80 and 90 %, mostly
accompanied by lower prediction accuracies for MCI
progression (Falahati et al. 2014b). The MCI group is
clinically quite heterogeneous. Some MCI subjects pro-
gress to AD or even other neurological disorders, some
remain stable over time, with a smaller number reverting to
a cognitively normal status (Mitchell and Shiri-Feshki
2009). In addition, one-year is a relatively short follow-up
time. When the subjects were followed for a longer period,
the accuracy increased. Including age in the models also
improved prediction accuracies. Although, the covariate
and detrended models performed similarly in terms of
model quality values, the detrended model induced the
highest accuracies in all settings.
A detailed analysis of correctly classified and incorrectly
classified subjects provided valuable information on the
age correction performance. As expected, younger AD
patients and older CTL subjects were more likely to be
misclassified. Similarly, younger MCI-p and older MCI-s
patients were prone to misclassification. These findings are
in line with previous studies (Dukart et al. 2011).
Incorrectly classified AD subjects had significantly higher
MMSE score compared to correctly classified AD subjects.
This can be explained by the previous finding that in AD
Table 4 Subjects’ characteristics in AD versus CTL classification: comparison between correctly/incorrectly classified subjects
AD versus CTL Classification CTL subjects AD patients Incorrect-
classified AD
versus CTL
Correct-
classified
Incorrect-
classified
p value Correct-
classified
Incorrect-
classified
p value p value
Uncorrected model
Count 309 31 243 54
Age, years 74.5 ± 5.6 79.1 ± 5.2 <0.001a 76.2 ± 6.7 73.3 ± 7.9 0.006a <0.001a
Education, years 14.3 ± 4.3 14.1 ± 5.5 0.839a 11.9 ± 4.8 12.8 ± 5.1 0.197a 0.294a
MMSE score 29.1 ± 1.1 28.9 ± 1.2 0.326a 21.8 ± 3.7 24.2 ± 2.8 <0.001a <0.001a
Gender, Male/Female 152/157 16/15 0.797b 107/136 25/29 0.762b 0.637b
ApoE-e4, N/P 217/87 26/5 0.138b 86/149 24/29 0.240b 0.001b
Cohort, ADNI/ANM 207/102 20/11 0.780b 141/102 34/20 0.505b 0.886b
Covariate model
Count 314 26 242 55
Age, years 74.8 ± 5.7 77.0 ± 4.3 0.058a 75.7 ± 6.8 75.4 ± 7.7 0.776a 0.237a
Education, years 14.2 ± 4.2 14.0 ± 5.6 0.781a 11.9 ± 4.7 12.5 ± 5.3 0.412a 0.269a
MMSE score 29.1 ± 1.1 28.9 ± 1.1 0.326a 21.7 ± 3.7 24.4 ± 2.7 <0.001a <0.001a
Gender, Male/Female 153/161 15/11 0.380b 103/139 29/26 0.171b 0.675b
ApoE-e4, N/P 223/84 20/5 0.385b 83/151 27/27 0.048b 0.012b
Cohort, ADNI/ANM 210/104 17/9 0.876b 143/99 32/23 0.902b 0.536b
Detrended model
Count 316 24 246 51
Age, years 75.0 ± 5.8 75.3 ± 4.6 0.756a 75.5 ± 7.0 76.3 ± 7.1 0.493a 0.553a
Education, years 14.4 ± 4.3 12.8 ± 5.6 0.205a 12.0 ± 4.8 12.4 ± 5.0 0.530a 0.756a
MMSE score 29.2 ± 1.1 28.8 ± 1.4 0.168a 21.8 ± 3.7 24.4 ± 2.7 <0.001a <0.001a
Gender, Male/Female 155/161 13/11 0.629b 105/141 27/24 0.180b 0.921b
ApoE-e4, N/P 225/87 18/5 0.524b 86/151 24/27 0.156b 0.012b
Cohort, ADNI/ANM 213/103 14/10 0.363b 144/102 31/20 0.767b 0.840b
p value in bold indicates statistically significant difference
Continuous data is represented as mean ± standard deviation, AD Alzheimer’s disease, CTL control subjects, ApoE apolipoprotein E, N/P
negative/positive for at least one e4 allele, MMSE mini mental state examination, ADNI/ANM Alzheimer’s disease Neuroimaging Initiative/
AddNeuroMed
a Independent-samples t test
b Pearson v2
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patients, decreased MMSE score correlates with gray matter
reduction (Frisoni et al. 2002) and correlates with aging
(Pradier et al. 2014). In MCI-s subjects, the mean MMSE
score was slightly higher in correctly classified subjects.
Interestingly, incorrectly classified MCI-s subjects were
more frequently ApoE-e4 positive compared to correctly
classified MCI-s (Table 5). This is in line with previous
studies that reported more regional atrophy in AD patients
with presence of genetic risk, especially in the medial
temporal cortex (Cherbuin et al. 2007; Ferreira et al. 2015;
van der Flier et al. 2011). The incorrectly classified MCI-s
subjects may thus have a high risk of developing AD in the
future.
The frequency of misclassification was higher in female
MCI-s subjects compared to males, indicating that more
female subjects had AD-like structural patterns. This is in
line with recent findings that the female sex is associated
with an increased risk of disease progression (Tifratene
et al. 2015). Although this difference exists even before age
correction, after correcting for age, more female subjects
were prone to be misclassified which could emphases the
role of age. This can support the age- by sex- related dif-
ferences in progression rates that proposed in several
studies (Mielke et al. 2014; Roberts et al. 2014).
The characteristics of correctly and incorrectly classi-
fied/predicted subjects were similar for both correction
approaches. In fact, the association between structural
brain changes, age, sex, ApoE genotype, cognitive status
and other factors are more complicated than pairwise
relations. Although the relationship between these factors
are explored from several perspectives such as age by sex
relations (Fratiglioni et al. 1997), sex by ApoE genotype
relation (Altmann et al. 2014), etc., the connection between
them is poorly understood. Considering age in multivariate
models, regardless of approach, can potentially enhance the
outcomes.
Table 5 Subjects’ characteristics in MCI prediction: comparison between correctly/incorrectly classified subjects
MCI prediction MCI-s subjects MCI-p subjects Incorrect-predicted
MCI-s versus MCI-p
Correct-
predicted
Incorrect-
predicted
p value Correct-
predicted
Incorrect-
predicted
p value p value
Uncorrected model Count 219 141 59 26
Age, years 73.6 ± 7.1 77.0 ± 6.1 <0.001a 75.0 ± 6.9 73.1 ± 5.3 0.220a 0.003a
Education, years 13.8 ± 4.6 14.1 ± 4.7 0.582a 13.8 ± 4.4 13.7 ± 3.8 0.820a 0.651a
MMSE score 27.4 ± 1.7 26.8 ± 1.6 0.001a 26.5 ± 1.9 26.6 ± 1.6 0.802a 0.682a
Gender, Male/Female 144/75 75/66 0.017b 35/24 15/11 0.888b 0.672b
ApoE-e4, N/P 118/87 65/71 0.077b 22/36 8/16 0.694b 0.190b
Cohort, ADNI/ANM 151/68 109/32 0.084b 44/15 18/8 0.609b 0.375b
Covariate model Count 219 141 60 25
Age, years 74.7 ± 7.1 75.3 ± 6.6 0.419a 74.3 ± 7.0 74.6 ± 5.0 0.852a 0.635a
Education, years 13.8 ± 4.6 14.2 ± 4.8 0.394a 13.9 ± 4.4 13.7 ± 3.9 0.853a 0.614a
MMSE score 27.4 ± 1.7 26.8 ± 1.7 0.001a 26.6 ± 1.9 26.4 ± 1.6 0.740a 0.383a
Gender, Male/Female 149/70 70/71 <0.001b 37/23 13/12 0.409b 0.828b
ApoE-e4, N/P 122/83 61/75 0.008b 20/39 10/13 0.418b 0.902b
Cohort, ADNI/ANM 150/69 110/31 0.050b 43/17 19/6 0.682b 0.824b
Detrended model Count 225 135 63 22
Age, years 75.2 ± 7.1 74.4 ± 6.6 0.273a 74.1 ± 6.9 75.4 ± 4.9 0.408a 0.492a
Education, years 13.8 ± 4.5 14.2 ± 4.8 0.478a 14.0 ± 4.1 13.2 ± 4.5 0.418T 0.380a
MMSE score 27.4 ± 1.7 26.7 ± 1.7 0.001a 26.5 ± 1.9 26.6 ± 1.6 0.775a 0.803a
Gender, Male/Female 154/71 65/70 <0.001b 39/24 11/11 0.329b 0.872b
ApoE-e4, N/P 127/83 56/75 0.001b 40/22 12/8 0.715b 0.817b
Cohort, ADNI/ANM 156/69 104/31 0.114b 46/17 16/6 0.979b 0.659b
p value in bold indicates statistically significant difference
Continuous data is represented as mean ± SD, MCI mild cognitive impairment, MCI-p progressive MCI, MCI-s stable MCI, ApoE
apolipoprotein E, N/P negative/positive for at least one e4 allele, MMSE mini mental state examination, ADNI/ANM Alzheimer’s disease
Neuroimaging Initiative/AddNeuroMed
a Independent-samples t test
b Pearson v2
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Conclusion
Both age correction approaches (age as a covariate and
detrending) could effectively eliminate the age differences
in classification and prediction results. Moreover, including
age in the models highlighted the role of the other disease-
related factors such as cognitive impairment and ApoE-e4
genotype. These results demonstrate that age is partially
masking other relevant factors such as ApoE genotype,
global cognitive impairment and sex. This is an important
finding, suggesting that mechanisms underlying the con-
founding effect of these factors should be further investi-
gated. At the time being, clinicians are already quite aware
about the effect of age when interpreting imaging data for
diagnostic purposes. Therefore, the other factors should
also be carefully considered when adjusting diagnostic
interpretations of imaging data in clinical settings. The
exact relationship between normal ageing and AD is far
from being fully understood at present and warrants further
investigations. Non-linear correction methods and other
alternatives for handling confounding factors should be
further investigated. Applying correction methods to other
confounding factors such as education and sex would be of
interest and could potentially improve prediction accuracy
of MCI progression further.
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